We describe the case of a 63-year-old female who presented with severe inflammatory spondylitis, refractory to various antibiotics. Mycobacterial and fungal osteomyelitis were unlikely. Although asymptomatic, she also had osteomyelitis in the sternocostoclavicular region, and was suspected of having synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO) syndrome, against which minocycline showed marked efficacy. The presence of severe inflammatory SAPHO, albeit rare, together with the marked efficacy of tetracycline, should be noted.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.3109/14397595.2013.874744 | DOI Listing |
Front Immunol
December 2024
School of Life Sciences, Beijing University of Chinese Medicine, Beijing, China.
The complex interaction between the immune system and autoinflammatory disorders highlights the centrality of autoimmune mechanisms in the pathogenesis of autoinflammatory diseases. With the exploration of PSTPIP2, it has been discovered to play an inhibitory role in immune diseases, suggesting its potential utility in the research and treatment of rheumatic diseases. This review outlines the mechanisms of PSTPIP2 in chronic multifocal osteomyelitis (CMO), rheumatoid arthritis (RA), synovitis-acne-pustulosis-hyperostosis-osteitis (SAPHO) syndrome, liver diseases, renal diseases, pressure ulcer sepsis and diabetic obesity.
View Article and Find Full Text PDFJ Dermatolog Treat
December 2024
Department of Dermatology, The Second Hospital of Dalian Medical University, Dalian, China.
Aim: SAPHO (synovitis, acne, pustulosis, hyperostosis and osteitis) syndrome is a rare autoimmune disorder characterized by typical cutaneous lesions (palmoplantar pustulosis and eruptive acne) and osteoarticular symptoms (aseptic osteomyelitis and joint inflammation). This study aims to evaluate the therapeutic efficacy and safety of Janus kinase 1 (JAK1) inhibitor abrocitinib in patients with SAPHO syndrome.
Methods: We presented a patient with SAPHO syndrome with accelerated disease progression who did not respond to traditional therapies.
Case Rep Rheumatol
October 2024
Division of Rheumatology, Mayo Clinic, Jacksonville 32224, Florida, USA.
SAPHO syndrome, a rare inflammatory disorder of bone, joints, and skin, is named based on the presence of synovitis, acne, pustulosis, hyperostosis, and osteitis. The hallmark of SAPHO syndrome includes osteoarticular and dermatologic manifestations, however, rarer associations with inflammatory bowel disease (particularly Crohn's disease) have been documented. The literature on the relationship between SAPHO syndrome and inflammatory bowel disease (IBD), especially ulcerative colitis (UC), remains limited.
View Article and Find Full Text PDFRheumatology (Oxford)
November 2024
Department of Orthopedics Medicine, Beijing Jishuitan Hospital, Capital Medical University, Beijing, China.
Objective: To evaluate the long-term effectiveness of the combination of Iguratimod (IGU) and Alendronate for patients with Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis (SAPHO) syndrome.
Methods: A prospective cohort study was conducted on patients diagnosed with SAPHO syndrome at Peking University Third Hospital and Beijing Jishuitan Hospital from 2017 to 2024. The initial treatment regimen comprised a combination of IGU and Alendronate.
Cureus
October 2024
Internal Medicine, Islamic International Medical College, Rawalpindi, PAK.
SAPHO syndrome (synovitis, acne, pustulosis, hyperostosis, osteitis syndrome) is a systemic inflammatory disease characterized by a combination of both osteoarticular and dermatological manifestations. We encountered an interesting case of a 54-year-old female patient who presented with symptoms of recurrent chest infections. Extensive investigations, including laboratory tests and imaging, were conducted with an initial suspicion of malignancy, but the patient was ultimately diagnosed with SAPHO.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!